Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for neurodegenerative diseases. Its lead candidate, zervimesine (CT1812), is a once-daily oral therapy designed to protect synapses by blocking toxic protein oligomers. Phase 2 studies have been completed in dementia with Lewy bodies, mild-to-moderate Alzheimer's disease and geographic atrophy secondary to dry age-related macular degeneration, and the Phase 2 START study in mild cognitive impairment and early Alzheimer's disease is ongoing. Following efficacy signals in the SHIMMER study, the company plans a registrational Phase 3 trial in DLB psychosis. Research is funded largely by National Institutes of Health grants.
Cognition Therapeutics is publicly traded
IPO'd on Oct 8, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under CGTX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2007
Employees
11–50
Total Funding
$157.5M
5 rounds
Closed $30M registered direct offering of 14.7M shares at $2.05/share to two institutional investors
Sets a $2.05/share primary pricing point; extended cash runway reduces near-term dilution urgency
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $157.5M across 5 rounds
Last updated 10-01-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Oct 8, 2021 | IPO Press release | $45.2M | $0.26B | |
| Mar 2021 | SAFE | $8.9M | — | Not disclosed |
| Mar 2018 | Convertible Notes | $13.0M | — | Not disclosed |
Lisa Ricciardi
Chief Executive Officer
Anthony O. Caggiano
Chief Medical Officer
John Doyle
Chief Financial Officer
Anita Cornet
Head of Quality
Theresa Devins
Vice President, Clinical Operations
Bobby Horn
Corporate Controller
Jennifer Iaci
Vice President, Development Operations
Steven A. Weissman
Vice President and Head of CMC
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Eli Lilly
Developing donanemab (Kisunla), an anti-amyloid monoclonal antibody approved by FDA for early symptomatic Alzheimer's disease with shorter, less frequent infusions.
Biogen/Eisai
Developing lecanemab (Leqembi), the first disease-modifying therapy approved for early symptomatic Alzheimer's disease (FDA approval July 2023).
Roche/AC Immune
Developing anti-tau and anti-amyloid therapies for neurodegenerative diseases including Alzheimer's disease.
Yes, Cognition Therapeutics is publicly traded under the ticker symbol CGTX on the NASDAQ. The company went public in Oct 8, 2021.
Cognition Therapeutics trades under the ticker symbol CGTX on the NASDAQ. It began trading in Oct 8, 2021.
Cognition Therapeutics (CGTX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CGTX to place an order.
Cognition Therapeutics went public in Oct 8, 2021 via ipo. Cognition Therapeutics has traded on Nasdaq as CGTX since its October 8, 2021 IPO at $12.00 per share and remains a listed clinical-stage company, funding itself since through public-market offerings including a $30 million registered direct offering at $2.05 per share in August 2025. Its lead candidate zervimesine (CT1812) has completed Phase 2 testing in dementia with Lewy bodies and in mild-to-moderate Alzheimer's disease. The company is preparing a registrational Phase 3 trial in DLB psychosis, which it aims to begin in mid-2027.
Cognition Therapeutics raised $157.5M across 5 disclosed funding rounds prior to its public listing.
Cognition Therapeutics is headquartered in Purchase, NY, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.